Dyne Therapeutics (DYN) Competitors $13.00 +0.42 (+3.34%) Closing price 04:00 PM EasternExtended Trading$13.15 +0.15 (+1.15%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYN vs. LEGN, RVMD, RYTM, RNA, AXSM, NUVL, ABVX, CRSP, MRUS, and VKTXShould you be buying Dyne Therapeutics stock or one of its competitors? The main competitors of Dyne Therapeutics include Legend Biotech (LEGN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Axsome Therapeutics (AXSM), Nuvalent (NUVL), Abivax (ABVX), CRISPR Therapeutics (CRSP), Merus (MRUS), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical products" industry. Dyne Therapeutics vs. Its Competitors Legend Biotech Revolution Medicines Rhythm Pharmaceuticals Avidity Biosciences Axsome Therapeutics Nuvalent Abivax CRISPR Therapeutics Merus Viking Therapeutics Dyne Therapeutics (NASDAQ:DYN) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation. Does the media favor DYN or LEGN? In the previous week, Legend Biotech had 1 more articles in the media than Dyne Therapeutics. MarketBeat recorded 11 mentions for Legend Biotech and 10 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.21 beat Legend Biotech's score of 0.98 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, DYN or LEGN? Legend Biotech has higher revenue and earnings than Dyne Therapeutics. Legend Biotech is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyne TherapeuticsN/AN/A-$317.42M-$3.86-3.37Legend Biotech$627.24M10.14-$177.03M-$0.88-39.32 Which has more risk & volatility, DYN or LEGN? Dyne Therapeutics has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Do insiders and institutionals hold more shares of DYN or LEGN? 96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 20.8% of Dyne Therapeutics shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is DYN or LEGN more profitable? Dyne Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -40.83%. Legend Biotech's return on equity of -32.00% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dyne TherapeuticsN/A -64.12% -56.75% Legend Biotech -40.83%-32.00%-20.07% Do analysts prefer DYN or LEGN? Dyne Therapeutics presently has a consensus price target of $34.07, indicating a potential upside of 162.05%. Legend Biotech has a consensus price target of $73.00, indicating a potential upside of 110.98%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Legend Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyne Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 3 Strong Buy rating(s) 3.06Legend Biotech 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryDyne Therapeutics beats Legend Biotech on 10 of the 16 factors compared between the two stocks. Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYN vs. The Competition Export to ExcelMetricDyne TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.79B$2.54B$5.82B$9.74BDividend YieldN/A1.68%4.40%4.08%P/E Ratio-3.3722.4130.1425.84Price / SalesN/A737.32459.10116.06Price / CashN/A26.0925.7828.79Price / Book2.105.529.425.99Net Income-$317.42M$31.83M$3.27B$265.29M7 Day Performance5.43%1.09%2.05%2.53%1 Month Performance30.65%0.83%3.58%0.92%1 Year Performance-72.06%6.98%30.09%18.70% Dyne Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYNDyne Therapeutics3.7361 of 5 stars$13.00+3.3%$34.07+162.1%-73.0%$1.79BN/A-3.37100News CoveragePositive NewsAnalyst UpgradeGap UpLEGNLegend Biotech3.8865 of 5 stars$37.45-0.1%$72.38+93.3%-38.2%$6.88B$627.24M-42.562,609News CoverageAnalyst ForecastRVMDRevolution Medicines4.3759 of 5 stars$36.45+0.4%$69.54+90.8%-15.2%$6.81B$11.58M-8.10250Positive NewsRYTMRhythm Pharmaceuticals3.7699 of 5 stars$98.09+0.5%$101.57+3.5%+123.9%$6.52B$130.13M-32.59140Positive NewsRNAAvidity Biosciences3.1339 of 5 stars$44.48-4.3%$67.00+50.6%+6.5%$5.72B$10.73M-12.49190Positive NewsInsider TradeAXSMAxsome Therapeutics4.7888 of 5 stars$111.13+1.8%$178.00+60.2%+34.7%$5.55B$385.69M-21.92380News CoveragePositive NewsNUVLNuvalent3.3723 of 5 stars$75.01-1.4%$119.60+59.4%-10.8%$5.41BN/A-15.3140News CoveragePositive NewsABVXAbivax2.7397 of 5 stars$70.01-0.6%$92.33+31.9%+566.2%$5.29BN/A0.0061Positive NewsCRSPCRISPR Therapeutics3.6359 of 5 stars$57.59-3.6%$71.60+24.3%+11.6%$5.24B$37.31M-10.61460Positive NewsMRUSMerus2.3435 of 5 stars$66.00-1.9%$88.50+34.1%+25.9%$4.99B$36.13M-12.0037Positive NewsAnalyst ForecastVKTXViking Therapeutics3.9403 of 5 stars$42.09+5.1%$86.92+106.5%-59.8%$4.73BN/A-27.5120 Related Companies and Tools Related Companies Legend Biotech Competitors Revolution Medicines Competitors Rhythm Pharmaceuticals Competitors Avidity Biosciences Competitors Axsome Therapeutics Competitors Nuvalent Competitors Abivax Competitors CRISPR Therapeutics Competitors Merus Competitors Viking Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DYN) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access